Reorganizing the system of care surrounding laparoscopic surgery: A cost-effectiveness analysis using discrete-event simulation

被引:33
作者
Stahl, JE
Rattner, D
Wiklund, R
Lester, J
Beinfeld, M
Gazelle, GS
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Cambridge, MA 02138 USA
[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Cambridge, MA 02138 USA
[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Cambridge, MA 02138 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Cambridge, MA 02138 USA
关键词
computer simulation; discrete event shnulotion; anesthesia; cost-effectiveness;
D O I
10.1177/0272989X04268951
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose. To determine the cost-effectiveness of a proposed reorganization of surgical and anesthesia core to balance patient volume and safety Methods. Discrete-event simulation methods were used to compare current surgical practice with a new modular system in which patient care is handed off between 2 anesthesiologists. A health core system's perspective, using hospital and professional costs, was chosen for the cost-effectiveness analysis. Outcomes were patient throughput, flow time, wait time, and resource use. Sensitivity analyses were performed on staffing levels, mortality rates, process times, and scheduled patient volume. Results. The new strategy was more effective (average 4.41 patients/d [median = 5] v. 4.29 [median = 4]) and had similar costs (average cost/patient/d = $5327 v. $5289) to the current strategy with an incremental cost-effectiveness of $318/additional patient treated/d. Surgical mortality rote must be >4% or hand-off delay>15 min before the new strategy is no longer more effective. Conclusion. The proposed system is more cost-effective relative to current practice over a wide range of mortality rates, hand-off times, and scheduled patient volumes.
引用
收藏
页码:461 / 471
页数:11
相关论文
共 41 条
  • [41] Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health-Care System in China
    Zhu, Chen
    Xing, Xiao-xuan
    Wu, Bin
    Liang, Gang
    Han, Gang
    Lin, Cai-xia
    Fang, Hong-mei
    FRONTIERS IN PHARMACOLOGY, 2021, 12